CF PharmTech's (HKG:2652) profit attributable to owners of the parent fell to 2.5 million yuan for 2025 from 21.1 million yuan a year earlier, according to a Monday Hong Kong bourse filing.
Earnings per share came in at 0.0066 yuan, compared with 0.0569 yuan a year earlier.
Revenue declined to 432.5 million yuan from 607.8 million yuan in 2024.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments